Base de données - (CIANE)

Présentation de cette base de données documentaires (site du CIANE)
Actuellement 3111 fiches
➡ Chaîne YouTube (tutoriel)

https://ciane.net/id=2806

Créée le : 26 Nov 2017
Modifiée le : 26 Nov 2017

➡ Modifier cette fiche
Ne suivez ce lien que si vous possédez un mot de passe d’éditeur !

Notice bibliographique (sans auteurs) :

Efficacy and safety of misoprostol compared with the dinoprostone for labor induction at term: A meta-analysis - Journal of Maternal-Fetal and Neonatal Medicine - Vol. 29, 8 - p.1297-1307

Auteur·e(s) :

Wang, L.; Zheng, J.; Wang, W.; Fu, J.; Hou, L.

Année de publication :

2016

URL(s) :

https://www.scopus.com/inward/record.uri?eid=2-s2.…
https://doi.org/10.3109/14767058.2015.1046828

Résumé (français)  :

Abstract (English)  :

Objective: The purpose of this study was to compare the efficacy and safety of intravaginal misoprostol and the dinoprostone vaginal insert for labor induction at term.Method: PubMed, EMBASE, MEDLINE, CNKI, EBSCO and the Cochrane Library were searched for articles published in English language from 2000 to 2014, Using the keywords misoprostol, dinoprostone, labor induction.Results: Eight of 436 studies (1669 women) identified met the criteria for meta-analysis. We assigned a quality rating to each included article. The use of misoprostol showed less oxytocin augmentation when compared with dinoprostone (RR = 0.78, 95% CI = 0.67-0.90). There was no difference in the risk of tachysystole (RR = 1.18, 95% CI = 0.78-1.79), uterine hyperstimulation (RR = 1.24, 95% CI = 0.75-2.06), vaginal delivery within 24 h (RR = 1.10, 95% CI = 1.00-1.20), cesarean delivery (RR = 0.84, 95% CI = 0.56-1.24), Neonatal Intensive Care Unit admission (RR = 0.86, 95% CI = 0.58-1.28), Apgar scores <7 in 5 min (RR = 1.18, 95% CI = 0.39-3.63) between misoprostol and dinoprostone.Conclusion: Misoprostol compared with dinoprostone appears to show less oxytocin augmentation for labor induction at term. The other outcomes of both drugs were similar. However, these findings were based on small-scale trials. Further studies assessing the effectiveness and safety of misoprostol and dinoprostone in selected groups of patients are warranted. © 2015 Informa UK Ltd.

Sumário (português)  :

Resumen (español)  :

Remarques :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Mots-clés :

➡ déclenchement ; misoprostol (Cytotec)

Auteur·e de cette fiche :

Import 26/11/2017 — 26 Nov 2017